[5] Liu B, Zhang Y, Wang D, Hu X, Zhang Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13 T cells to immune-checkpoint blockade. Nat Cancer. 2022 Sep;3(9):1123-1136. doi: 10.1038/s43018-022-00433-7. Epub 2022 Sep 22. PMID: 36138134....
同样是今年,在Nature Cancer杂志上发表了另一篇一篇名为“The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response”的文章,首次证实了CXCL13+ T细胞可以通过和树突细胞(DC)相互作用来发挥重要的抗肿瘤功能。这项研究的作者通过单细胞测序...
CXCL13+肿瘤反应性CD8 T细胞亚群在免疫治疗中的比例变化 作者发现在非小细胞肺癌中,治疗前肿瘤内的CXCL13+肿瘤反应性CD8 T细胞主要由terminally differentiated T cells构成,而治疗后precursor-like T cells增加。在皮肤细胞癌中terminally differentiated T cells一直占据统治地位。而在乳腺癌中现象因治疗方式而异,只用an...
题目:Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade 期刊:Nature Cancer IF:23.177 发表时间:2022年9月22日 通讯作者单位:北京大学 DOI:https://doi.org/10.1038/s43018-...
在免疫治疗领域,探索肿瘤反应性T细胞对免疫检查点阻断(ICB)的响应机制一直是研究热点。一篇2022年发表在《Nature Cancer》上的研究——“Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade”为我们揭示了CXCL13+ T细胞在ICB治疗中的关键作用。虽然不是最新的...
题目:Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade 期刊:Nature Cancer IF:23.177 发表时间:2022年9月22日 通讯作者单位:北京大学 DOI:https://doi.org/10.1038/s43018-022-00433-7
3. 3. Ortonne N, Dupuis J, Plonquet A, et al. Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL). Am J Surg Pathol 2007; 31:1068-76
Duan Z, Gao J, Zhang L, et al. Phenotype and function of CXCR5+CD45RA-CD4+ T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis. Oncotarget. 2015;6(42)...
CXCL13-producing PD-1hiCXCR5CD4 T cells were discovered in synovial tissues of rheumatoid arthritis (RA). Further intensive analysis of RA samples led to the proposal of PD-1hiCXCR5CD4 T cells as a pathogenic CD4 subset, peripheral helper T (Tph) cells. Tph cells are upregulated also in ...
(BLC) is a chemokine ligand. It is expressed in secondary lymphoid tissue by stromal cells within B-cell follicles and by follicular dendritic cells, macrophages, and germinal center T cells. The CXCL13 receptor CXCR5 is expressed on follicular B cells. CXCL13 interaction with its receptor ...